

BizInt Smart Charts

Patents & IP Sequences | Clinical Trials | Drug Pipelines

Workshop - Proposed MARPAT support in BizInt Smart Charts for Patents

3 June 2020, incorporating feedback from the workshop

John Willmore, VP Product Development Diane Webb, President

www.bizint.com

Notes from the Workshop

- Thank you for your participation and for all the excellent feedback.
- These slides have been updated to incorporate some clarifications and additional ideas.
- New content is in purple text.

Background

- Customers have been requesting MARPAT support in BizInt Smart Charts for Patents for several years.
- One customer just gave us a detailed design for what they would like to see.
- To implement MARPAT support, we need a BizInt export on STNext.



Purpose of today's workshop

- Present proposed MARPAT support in BizInt Smart Charts for Patents.
- Get your feedback would you find this valuable?
- If so, encourage you to contact STN!

Our Ask

- File format problems continue to be our #1 support issue on STN
- Please ask CAS/STN to implement a BizInt export format on STNext
- This is an export format, like RTF
- We will communicate specifics to CAS/STN
- Everything that follows in this presentation depends on getting a BizInt export in place or STNext

Today's Topics

- Display Formats
- Presentation in Charts
- Image quality
- Presentation in Index of Hit Structures
- Your feedback

Current Display (Version 5.3)

	Title	Inventor(s) Pa	Patent Assignee	Patent Family			Driority Data	Craphic Information
	The			Patent	Kind	Date	Priority Date	Graphic Information
1	Pyrrolopyridine derivatives as	Cacatian, Salvacion	Vitae	WO 2018053267	A1	20180322	2016-09-16	1290
	inhibitors of the menin-MLL	Claremon, David A.	Pharmaceuticals,	CA 3036987	A1	20180322		G17 Ak
	interaction and their preparation	Dong, Chengguo	Inc., USA	AR 109658	A1	20190109		67 617 61
		Fan, Yi		AU 2017326006	A1	20190321		G20
		Jia, Lanqi		IL 265028	Α	20190430		
		Lotesta, Stephen D.		BR 112019005030	A2	20190618		GI7 AK
		Singh, Suresh B.	•	MX 2019003091	Α	20190708		Gi8 Gi7 G20 G20
		Venkatraman, Shankar	3	EP 3512850	A1	20190724		G20
		Yuan, Jing		KR 2019111008	Α	20191001		
		Zheng, Yajun		CN 110325533	Α	20191011		
		Zhuang, Linghang		JP 2019529421	Т	20191017		
		Endang, Englishing		IN 201927007880	Α	20190802		
				US 20190202830	A1	20190704		
2	Neuroactive compounds	Quirk, Michael C.	Sage Therapeutics,	WO 2016057713	A1	20160414	2014-10-07	Q. G26
	comprising NMDA receptor	Doherty, James J.	Inc., USA	CA2963938	A1	20160414		0 <u>9</u> 26
	modulators and methods of use	Martinez Botella,		AU 2015330906	A1	20170427		
	for treating sterol synthesis	Gabriel		IL 251505	Α	20170529		0-Ch. AK
	disorders or sterol deficiency			KR 2017065637	Α	20170613		336 S 281 N-Ak
	disorders			EP 3204011	A1	20170816		367 N 270 G1
				JP 2017530982	Т	20171019		
				CN 107405352	Α	20171128		
			BR 112017007053	A2	20180619			
			MX 2017004684	Α	20170630			
				US 20170304321	A1	20171026		
				ZA2017002545	Α	20190626		
				IN 201717014604	A	20170915		

MARPAT Display Formats

 BIB AB FQHIT **BIB AB QHIT BIB ABS FQHIT**

...

<pre>1266: carbon chain <cou bonds> (opt. substd.) 1531: heterocycle <con more N, zeto or more O, bonds> (opt. substd. b) 1855: alkylene <contain Patent location: Note: Note:</contain </con </cou </pre>
MSTR 1A
612 612 612 617 617 617 617
G1 = 216-11 217-7
2826-2825
<pre>G8 = carbon chain <</pre>
G25 = heterocycle <c 1 or more heter</c
zero or more S 0 or more doub! G26 = 237-11 238-217 279-11 281-217

© 202	20 BizInt	Solutions,	Inc	www.bizint.com
		socacions,	III C	

in an iduit i-						
HAVE REQUESTED DATA FROM 14 ANSWERS - CONTINUE? Y/(N):y						
ANSWER 1 OF 14 MARPAT COPYRIGHT 2020 ACS ON STM 105:57011 MARPAT full-test 105:57011 MARPAT full-test ball preparation Coexian, Salvestion Classeon, David A.: Dong, Chengguo: Fan, Yi; Jia, Langi Locets, Stephen D.; Singh, Suceth B.; Venkstraman, Shanker; Yuan, Jung; Ibeng, Yayun; Ibang, Linghang Yizaw Faramaseuticals, Inc., USA Vizaw Faramaseuticals, Inc., USA						
Patent						
English						
CNT 1	1					
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE		
WO 2018053267	A1	20180322	WO 2017-US51780 CA 2017-3036987 AR 2017-102556	20170915		
CA 3036987	A1	20180322	CA 2017-3036987	20170915		
AR 109658	A1	20190109	AR 2017-102556	20170915		
AU 2017326006	A1	20190321	AU 2017-326006 IL 2017-265028	20170915 20170915		
IL 265028	A	20190430	IL 2017-265028			
BR 112019005030	A2	20190618	BR 2019-112019005030	20170915		
MX 2019003091	A	20190708	MX 2019-3091 EF 2017-772585	20170915		
KR 2019111008	A	20191001	<pre>KR 2019-7010730 CN 2017-80063763</pre>	20170915		
CN 110325533	A	20191011	CN 2017-80063763			
JP 2019529421	т	20191017		20170915		
IN 201927007880	A	20190802	IN 2019-27007880 US 2019-16333852	20190228		
US 20190202830	A1	20190704	US 2019-16333852	20190315		
US 2016-62395618 WO 2017-US51780		20160916				
CASREACT 168:36701						
			lopyridine derivs. of f			
			enin with MLL and MLL f			
			same, and their use in '			
cancer and other diseases mediated by the menin-MLL interaction. Compds.						
of formula I wherein A is C6-10 aryl, 5- to 14-membered heteroaryl, C3-14						
cycloalkyl, 4- to 14-membered heterocycloalkyl; U is CRa and N; Ra is H,						
halo, CN, OH, etc.; V and W are independently N and C; Y is CRb, CO and						
CS; Rb is H, halo, CN, OH, C1-4 alkyl, etc.; dashed bonds are						
independently single and double bond; X is F and Cl; Z is halo, C1-6						
alky1, C2-6 alkeny1, CN, NO2, etc.; n and m are independently 0 and 1; p						
is 0, 1, 2 and 3; q is 0, 1 and 2; L is C1-6 alkylene and (C1-4						

altyj, C2-4 altenyj, C3, NG2, etc.; n and m are independently 9 and 1; p is 0, 1; 2 and 3; q is 0, 1 and 2; l is C-4 altylene 0.4-0-(C1-4 altylene 0.4-0-(C1-4 altylene 0.4-0-(C1-4 altylene 0.4-0)-(C1-4 altylene 0.4-0; c1-3 cycloslyl), c1-3 cycloslyl), c1-4 cycloslyl, c2-4 altylene cycloslyl, c1-4 cycloslyl, c2-4 altylene cycloslyl, c2-4 altylene cycloslyl, c2-4 altylene cycloslyl, c2-4 altylene cycloslyl, c2-4 alteryl, etc.; and pharmacemically balancially careful cycloslyl, c2-4 alteryl, etc.; and pharmacemically by bydrolym carefur barrs. A cycloslyl, c2-4 alteryl, etc.; and pharmacemically bydrolym carefurber cycloslyl, c2-4 alteryl, etc.; and pharmacemically bydrolym carefurbers. A cycloslyl, c2-4 alteryl, etc.; and pharmacemically c2-4 alteryl-1-4 cyclosed independently B, balancially c2-4 cycloslyl, c2-4 alteryl-1-4 cyclosed independently B, balancially c2-4 cycloslyl, c2-4 alteryl-1-4 cyclosed independently B, balancially c2-4 cycloslyl, c2-4 cyclosl MSTR 14 Assembled

i bib ab fghit 1-

PRAI

containing 1-6 C, 0 or more double bonds, 0 or more triple ntaining up to 14 atoms, 1 or more heteroatoms, zero or 0, zero or more S (no other heteroatoms), 0 or more double aining 1 or more C> (opt. substd.) claim 1 or pharmaceutically acceptable salts substitution is restricted additional derivatization also claimed

<containing 1-6 C. able bonds. 0 or more triple bonds>

<containing up to 14 atoms, teroatoms, zero or more N, zero or more O, S (no other heteroatoms) ble bonds> (opt, substd, by 1 or more G8) / 258-11 259-217 /

2578 2589 2530 2538 2538 2538 -631 2538

RE.CNT 3

= alkylene <containing 1 or more C> (opt, substd.) G28 = alkylene G30 = S G32 = O Patent location: Note: Note: Note: claim 1 or pharmaceutically acceptable salts

ALL CITATIONS AVAILABLE IN THE RE FORMAT

substitution is restricted additional derivatization also claimed THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD **BIB AB** (Supported today)


Assembled Structure(s)

Unassembled Structure

Display Format Limitations

- Assembled structures only
- Unassembled structures will be ignored Suggestion: "Assembled structure not available" in the event of a hit structure without assembled structure
- Not sure whether QHITEXG format will work yet (are G-group descriptions text only vs. text + structures?)

Data Elements (Columns)




Proposed New Columns

MARPAT: Proposed New Fields

Title	First Hit Structure	Patent Location	Node Annotations	Structure Notes
1 Pyrrolopyridine derivatives as inhibitors of the menin-MLL interaction and their preparation	G17 G2 AK S 0 0	claim 1	1266: carbon chain <containing 1-6 C, 0 or more double bonds, 0 or more triple bonds> (opt. substd.) 1831: heterocycle <containing th="" up<=""><th>or pharmaceutically acceptable salts substitution is restricted additional derivatization also claimed</th></containing></containing 	or pharmaceutically acceptable salts substitution is restricted additional derivatization also claimed
	Giê Gi7 G20 g20 G20		to 14 atoms, 1 or more heteroatoms, zero or more N, zero or more O, zero or more S (no other heteroatoms), 0 or more double bonds> (opt. substd. by 1 or more	
		b	G8) 1855: alkylene <containing 1="" or<br="">more C> (opt. substd.)</containing>	


Proposed Column: First Hit Structure

- Add to both CAplus and MARPAT
- Shows first hit structure
- In addition to GI (Abstract Structure)
- Question from the workshop is how to display both CAPLUS and MARPAT hit structures
 - Separate columns?
 - Summarize rule in Reference Rows?




Structure Image Quality

- BizInt isn't handling the latest STNext structure displays well
- Improve resolution
- Support color hit indications (option?)
- REGISTRY, CAPLUS, and MARPAT



Proposed Column: Patent Location

- Patent location for first hit structure (from structure annotations)
- Patent Location not limited to claims
- We could also capture a deduplicated list of claim numbers (only) from all hits in a record "Claimed Structure Locations"
- Would investigate whether it is possible to capture additional claim locations from Notes



Proposed Column: Node Annotations

• List of node annotations from the first assembled hit structure, as paragraphs

Node Annotations

1266: carbon chain <containing 1-6 C, 0 or more double bonds, 0 or more triple bonds> (opt. substd.) 1831: heterocycle <containing up to 14 atoms, 1 or more heteroatoms, zero or more N, zero or more O, zero or more S (no other heteroatoms), 0 or more double bonds> (opt. substd. by 1 or more G8) 1855: alkylene <containing 1 or more C> (opt. substd.)

Proposed Column: Structure Notes

- List of notes from the first assembled hit structure, as paragraphs
- Includes Stereochemistry
- "Note:" prefixes removed

Structure Notes

or pharmaceutically acceptable salts substitution is restricted additional derivatization also claimed

Proposed Column: Additional G-groups

- (Added based on workshop feedback)
- List of additional G-groups from QHITEXG display format

Additional G-groups

G1 = alkyl <containing 1-10 C> / any ring <containing zero or more N, zero or more O, zero or more S (no other heteroatoms), aromatic, 1-3 rings, including 5- or 6-membered rings> (opt. substd. by G7) / (Specifically claimed: Me / Ph (opt. substd. by G7)) / (Examples: Et / Pr-n / Pr-i / Bu-n / Bu-i / Bu-s / Bu-t)


G3 = H/R

Proposed Column: Num Hit Structures

- (Added based on workshop feedback)
- A simple column with the number of hit structures for the reference.
- This would be available in both CAPLUS and MARPAT charts

Integrating MARPAT in the Index of Hit Structures


- Creating an equivalent to the CAPLUS hit structure display in summary records
- Lists all assembled hit structures and annotations under the reference
- In Reference Rows, a family could have both HITSTR and QHIT displays



Integrating MARPAT in the Index of Hit Structures

- Index will be a structure list, rather than an index. Each structure to point to a single reference.
- Is it possible to equate assembled hit structures from different famililes?
- A simple difference in node numbering would result in image differences.


Index of Hit Structures



Integrating MARPAT in the Index of Hit Structures (II)

- We envision this being a separate table from the CAPLUS hit structures index
- A similar presentation could be created for REGISTRY
- As with the existing Index of Hit Structures, this will be an optional display

Index of Hit Structures



Actions - You

- Contact your STN Account Manager to request a BizInt export!
- Send us sample transcripts of edge cases we need to worry about
- Feedback and suggestions

Actions - STN

Implement a BizInt export option on STNext

Actions - BizInt

- Adjust STN parser to capture the assembled Markush and related data, skip all unassembled structure sections, populate new columns
- First hit structure column
- Improve STNext image quality
 - Full resolution images
 - Color highlights (Markush and Hit Structures)
- Add MARPAT support to Index of Hit Structures

THE JOURNEY CONTINUES...



support@bizint.com

Feedback?